The evidence is solid but not definitive, as the conclusions rely on the absence of changes in spatial breadth and would benefit from clearer statistical justification and a more cautious ...

Gline laid out a catalyst-rich 2026, stating, "The Phase IIb data for mostly is expected firmly in the second half of this year. We now know that because the study is fully enrolled, obviously. Same ...

– CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Receptor Sequences, Underlining Broad-Spectrum Antiviral Effects of Vidofludimus Calcium – "Together, our two poster presentations ...

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...

Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study ...

WALTHAM, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to ...

CEO Matthew Gline opened the call highlighting "positive Phase II results for brepocitinib and cutaneous sarcoidosis and Roivant's financial results for the third quarter ended December 31, 2025." He ...

This study presents a potentially valuable exploration of the role of thalamic nuclei in language processing. The results will be of interest to researchers interested in the neurobiology of language.

- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week ...

Radio spectrum is pricey. Operators drop billions at auction to lock down licensed frequency bands, and every single frequency counts. Dynamic Spectrum Sharing (DSS) was built to address exactly this, ...